Genscript Biotech (HKG:1548) rotating Chief Executive Officer Liu Zhenyu will step down effective Dec. 31, citing "personal career development," according to a Monday filing with the Hong Kong Exchange.
Liu also stepped down as chairman of subsidiary Probio Technology, effective Dec. 1.
Shao Weihui will stay as rotating CEO, while Li Zhu will succeed Liu as chairman at Probio.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.